| Literature DB >> 36267332 |
Sara Cappelli1, Alida Spalloni2, Fabian Feiguin3, Giulia Visani1, Urša Šušnjar1, Anna-Leigh Brown4, Marco De Bardi5, Giovanna Borsellino5, Maria Secrier6, Hemali Phatnani7, Maurizio Romano8, Pietro Fratta4,6, Patrizia Longone2, Emanuele Buratti1.
Abstract
Many lines of evidence have highlighted the role played by heterogeneous nuclear ribonucleoproteins in amyotrophic lateral sclerosis. In this study, we have aimed to identify transcripts co-regulated by TAR DNA-binding protein 43 kDa and highly conserved heterogeneous nuclear ribonucleoproteins which have been previously shown to regulate TAR DNA-binding protein 43 kDa toxicity (deleted in azoospermia-associated protein 1, heterogeneous nuclear ribonucleoprotein -Q, -D, -K and -U). Using the transcriptome analyses, we have uncovered that Nitric Oxide Synthase 1 Adaptor Protein mRNA is a direct TAR DNA-binding protein 43 kDa target, and in flies, its modulation alone can rescue TAR DNA-binding protein 43 kDa pathology. In primary mouse cortical neurons, we show that TAR DNA-binding protein 43 kDa mediated downregulation of Nitric Oxide Synthase 1 Adaptor Protein expression strongly affects the NMDA-receptor signalling pathway. In human patients, the downregulation of Nitric Oxide Synthase 1 Adaptor Protein mRNA strongly correlates with TAR DNA-binding protein 43 kDa proteinopathy as measured by cryptic Stathmin-2 and Unc-13 homolog A cryptic exon inclusion. Overall, our results demonstrate that Nitric Oxide Synthase 1 Adaptor Protein may represent a novel disease-relevant gene, potentially suitable for the development of new therapeutic strategies.Entities:
Keywords: ALS; CAPON/NOS1AP; RNA stability; TDP-43; hnRNPs
Year: 2022 PMID: 36267332 PMCID: PMC9576154 DOI: 10.1093/braincomms/fcac242
Source DB: PubMed Journal: Brain Commun ISSN: 2632-1297